<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6963661\results\search\funders\results.xml">
  <result pre="In hindsight it is therefore not surprising that the tetravalent" exact="Sanofi" post="CYD-TDV vaccine consisting E and prM caused increased virulence"/>
  <result pre="only approved tetravalent live attenuated chimeric dengue vaccine (CYD-TDV) by" exact="Sanofi" post="Pasteur [173], also known as DengvaxiaÂ® is believed to"/>
  <result pre="contain CD8 inducing non-structural dengue proteins that are absent from" exact="Sanofi" post="CYD-TDV, however, they also contain structural proteins raising the"/>
  <result pre="on previous infections. Once such example of this is the" exact="Sanofi" post="antibody-based vaccine which showed limited efficacy and elicited ADE"/>
  <result pre="Oxford Martin Fellow. This work was supported by the UK" exact="Department of Health" post="through Innovate UK &quot;New vaccines for global epidemics: development"/>
  <result pre="of a Zika vaccine). This research is funded by the" exact="Department of Health" post="and Social Care using UK Aid funding and is"/>
  <result pre="those of the author(s) and not necessarily those of the" exact="Department of Health" post="and Social Care. Conflicts of Interest The authors J.B."/>
 </snippets>
</snippetsTree>
